Related references
Note: Only part of the references are listed.Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications
Carolin Zwadlo et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Resistant hypertension and target organ damage
Maria Lorenza Muiesan et al.
HYPERTENSION RESEARCH (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances
Paolo Galuppo et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing
Samnang Tep et al.
JOURNAL OF LIPID RESEARCH (2012)
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
Tatiana I. Novobrantseva et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery
Bin Shi et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids
Marija Tadin-Strapps et al.
JOURNAL OF LIPID RESEARCH (2011)
Systemic Administration of Combinatorial dsiRNAs via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice
Jiehua Zhou et al.
MOLECULAR THERAPY (2011)
ApoB siRNA-induced Liver Steatosis is Resistant to Clearance by the Loss of Fatty Acid Transport Protein 5 (Fatp5)
Brandon Ason et al.
LIPIDS (2011)
An overview of candesartan in clinical practice
Zeeshan Khawaja et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2011)
Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment
Marc T. Abrams et al.
MOLECULAR THERAPY (2010)
Cardio classics revisited - focus on the role of candesartan
Maria Leonarda De Rosa
VASCULAR HEALTH AND RISK MANAGEMENT (2010)
RNA interference targeting the ACE gene reduced blood pressure and improved myocardial remodelling in SHRs
Junhua He et al.
CLINICAL SCIENCE (2009)
Overcoming obstacles to develop effective and safe siRNA therapeutics
Leiming Li et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
MicroRNA-like off-target transcript regulation by siRNAs is species specific
Julja Burchard et al.
RNA (2009)
Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes
Satoru Sonoke et al.
CANCER RESEARCH (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
RNAi therapeutics: Principles, prospects and challenges
Lars Aagaard et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Specific β1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia
Anne-Sophie Arnold et al.
JOURNAL OF HYPERTENSION (2007)
Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis
M Khoury et al.
ARTHRITIS AND RHEUMATISM (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
DV Morrissey et al.
NATURE BIOTECHNOLOGY (2005)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
DV Morrissey et al.
HEPATOLOGY (2005)
Global burden of hypertension: analysis of worldwide data
PM Kearney et al.
LANCET (2005)
Clinical pharmacokinetics of candesartan
CH Gleiter et al.
CLINICAL PHARMACOKINETICS (2002)
Gene therapy for hypertension: sense and antisense strategies
MI Phillips
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man
B Fuchs et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2000)
Antisense inhibition of β1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats
YC Zhang et al.
CIRCULATION (2000)
Share Paper
